Arcutis Submits Supplemental New Drug Application for Zoryve® (Roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
Arcutis向FDA提交了Zoryve®（Roflumilast）泡沫劑的補充新藥申請，用於成人和12歲以上青少年的頭皮和身體牛皮癬治療。